The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2014 ACR/ARHP Annual Meeting: Macrophage Activation Syndrome

2014 ACR/ARHP Annual Meeting: Macrophage Activation Syndrome

April 1, 2015 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
  • Macrophage Activation Syndrome
  • Ebola: Hemorrhagic Fever and Macrophage Activation Syndrome
Explore This Issue
April 2015
Also By This Author
  • Racial Disparities in Rheumatology: What Are We Doing About It?
Table 1: New Classification Criteria for MAS
click for large version
Table 1: New Classification Criteria for MAS

BOSTON—In a session on the role of macrophages in rheumatic diseases, Macrophages Gone Wild, at the ACR/ARHP Annual Meeting in Boston, November 2014, a panel of experts walked participants through the pathogenesis of and new classification criteria for macrophage activation syndrome (MAS), a severe complication of rheumatic diseases characterized by inflammatory multi-organ failure and hyperferritinemia. Although the complication occurs primarily in the setting of systemic juvenile idiopathic arthritis (sJIA), the presence of MAS outside of this setting was also discussed.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Pathogenesis of MAS

Although MAS, in part, got its name from the thought that hemophagocytosis is a primary pathological driver of the disease, Edward M. Behrens, MD, Joseph Lee Hollander Chair in Pediatric Rheumatology, chief, Division of Rheumatology, The Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, opened the session saying that hemophagocytosis is emerging as less of a driver than previously thought.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
Dr. Behrens
Dr. Behrens

As such, he prefers calling this syndrome “cytokine storm syndrome” because of the multiple cytokines being spewed out by the immune systems that lead to systemic inflammatory response caused by the environment, genetic factors or combined factors.

Focusing on genetic-related MAS, he talked about the common pathogenesis of MAS and familial hemophagocytic lymphohistiocytosis (FHL). Important for the pathogenesis of both MAS and FHL, he said, is a combination of both defects in cytotoxic cell killing, as well as cytokine effects. Key cytokines involved in the pathogenesis include numerous proinflammatory interleukins (ILs), including IL-6, IL-4, IL-1/18 and IL-33, as well as interferon-gamma.

‘We need to recognize what’s been happening in the past, but we need to stop wasting time & dollars on unimportant research.’

—Andrew R. Hoellein, MD

He also emphasized that despite the similarities between MAS and FHL, their fundamental pathoetiologies are likely to be different. For example, in FHL, a defect in cytotoxic granule release from CD8+ T cells is a necessary factor, but insufficient for disease development. In MAS, some cases may be due in part to defective cytotoxic granule function, but inflammation-induced cytokines modify or completely supplant this effect.

Although this moves us to a closer understanding of the pathogenesis of MAS, Dr. Behrens emphasized that more work needs to be done to understand how inflammation-induced cytokines may modify the effect of defective cytotoxic granule function on the development of MAS. Potential areas of inquiry include whether hypercytokinemia allow hypomorphic CTL function to reveal itself as MAS and which scenarios don’t require hypomorphic CTL function to turn into MAS.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: ACR/ARHP Annual Meeting, cytokine storm syndrome, macrophage activation syndrome, Nierengarten, Research, Rheumatic DiseaseIssue: April 2015

You Might Also Like:
  • New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
  • Macrophage Activation Syndrome
  • Ebola: Hemorrhagic Fever and Macrophage Activation Syndrome
  • 2014 ACR/ARHP Annual Meeting: Psoriatic Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)